je.st
news
Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines
2013-06-12 14:00:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Associations (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA (sitagliptin). Language: English Contact HTML: MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: other
profile
review
safety
Category:Biotechnology and Pharmaceuticals